Your browser doesn't support javascript.
loading
ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Reid, Tony R; Abrouk, Nacer; Caroen, Scott; Oronsky, Bryan; Stirn, Meaghan; Larson, Christopher; Beale, Keola; Knox, Susan J; Fisher, George.
Afiliação
  • Reid TR; Moores Cancer Center, La Jolla, CA.
  • Abrouk N; Clinical Trials Innovations, Mountain View, CA.
  • Caroen S; EpicentRx, Torrey Pines, CA.
  • Oronsky B; EpicentRx, Torrey Pines, CA. Electronic address: boronsky@epicentrx.com.
  • Stirn M; EpicentRx, Torrey Pines, CA.
  • Larson C; Moores Cancer Center, La Jolla, CA.
  • Beale K; Kaiser Permanente, Honolulu, HI.
  • Knox SJ; Stanford Medical Center, Palo Alto, CA.
  • Fisher G; Stanford Medical Center, Palo Alto, CA.
Clin Colorectal Cancer ; 22(1): 92-99, 2023 03.
Article em En | MEDLINE | ID: mdl-36529613
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais Idioma: En Ano de publicação: 2023 Tipo de documento: Article